Search Results | MSF Science Portal

Journal Article

|

Review

Ndlovu Z, Moore A, Casas EC, Fatti G

2025-05-01 • Lancet HIV

Journal Article

|

Review

Cortes CP, Sued O, Wong WCW, Borquez A, Ssonko C, et al.

2024-11-01 • Lancet HIV

Journal Article

|

Letter

Venter WDF, Gandhi M, Sokhela S, Sikwese K, Bygrave H, et al.

2024-10-01 • Lancet HIV

Journal Article

|

Commentary

Flores A, Tut Chol B, Alphonse J, Hewett T

2024-08-21 • Lancet HIV

Journal Article

|

Research

Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, et al.

2023-05-22 • Lancet HIV

BACKGROUND
The drug-drug interaction between rifampicin and dolutegravir can be overcome by supplemental dolutegravir dosing, which is difficult to implement in high-burden settings....

Journal Article

|

Research

Schramm B, Temfack E, Descamps D, Nicholas S, Peytavin G, et al.

2022-08-01 • Lancet HIV

BACKGROUND
Many countries are now replacing non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) with a regimen containing tenofovir d...

Journal Article

|

Research

Ford NP, Shubber Z, Meintjes GA, Grinsztejn B, Eholie SP, et al.

2015-08-11 • Lancet HIV

Journal Article

|

Commentary

Reuter A, Furin J

2018-09-08 • Lancet HIV

Journal Article

|

Commentary

Barber M, Sarpatwari A, Cepuch C

2021-12-07 • Lancet HIV

Journal Article

|

Commentary

Reuter A, Furin J

2020-07-02 • Lancet HIV

“We were hungry all the time”, is the first thing a 28-year-old tuberculosis survivor from rural Haiti told one of us (JF) when asked in 2017 about his experience of being treated for th...

Journal Article

|

Commentary

Isaakidis P, Gupta S, Das M, Ferrer D, Nalinikanta R, et al.

2015-09-24 • Lancet HIV

Journal Article

|

Commentary

Furin J, Isaakidis P

2016-02-02 • Lancet HIV

Journal Article

|

Research

Cornell M, Johnson LF, Schomaker M, Tanser F, Maskew M, et al.

2015-08-03 • Lancet HIV

BACKGROUND
As access to antiretroviral therapy (ART) expands, increasing numbers of older patients will start treatment and need specialised long-term care. However, the effect of ag...

Journal Article

|

Commentary

Reuter A, Furin J

2022-04-01 • Lancet HIV

Vika began to tremble uncontrollably as the car her family spent their entire savings on approached the hospital. Although she willed herself to stop, her emaciated frame shook with the ...

Journal Article

|

Research

Dhana A, Hamada Y, Kengne AP, Kerkhoff AD, Rangaka MX, et al.

2022-04-01 • Lancet HIV

BACKGROUND
Since 2011, WHO has recommended that HIV-positive inpatients be routinely screened for tuberculosis with the WHO four-symptom screen (W4SS) and, if screened positive, rece...

Journal Article

|

Commentary

Ndlovu Z, Burton R, Stewart RC, Bygrave H, Roberts TR, et al.

2020-05-27 • Lancet HIV

Journal Article

|

Research

Ford NP, Patten GE, Rangaraj A, Davies MA, Meintjes GA, et al.

2022-03-01 • Lancet HIV

BACKGROUND
The identification and appropriate management of people with advanced HIV disease is a key component in the HIV response. People with HIV who are hospitalised are at a hig...

Journal Article

|

Research

Cohn J, Whitehouse K, Tuttle J, Lueck K, Tran TH

2016-10-01 • Lancet HIV

Journal Article

|

Review

Schaefer R, Amparo da Costa Leite PH, Silva R, Abdool Karim Q, Akolo C, et al.

2022-03-07 • Lancet HIV

BACKGROUND
Previous WHO guidance on tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis (PrEP) suggests measuring creatinine levels at PrEP initiation and regularly aft...

Journal Article

|

Commentary

Furin J, Isaakidis P

2017-03-01 • Lancet HIV

Science Portal

Lateral flow assay-based CD4 cell count testing for advanced HIV disease

Humanising and optimising HIV health care for refugees and asylum seekers

The long wait for long-acting HIV prevention and treatment formulations

Complex response to HIV and tuberculosis in South Sudan

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial

Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study

Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis

Reducing harm in the treatment of multidrug-resistant tuberculosis

COVID-19 antivirals must not affect HIV drug supply

The problem with vitamin D supplementation for tuberculosis

HIV viral load messages should go viral in India

The Tuberculosis Emergency in Eastern Europe

Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study

Helping hospitals heal people with HIV and tuberculosis

Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis

Framework for the implementation of advanced HIV disease diagnostics in sub-Saharan Africa: programmatic perspectives

Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis

Paediatric HIV testing beyond the context of prevention of mother-to-child transmission: a systematic review and meta-analysis

Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data

Life in the time of antiretrovirals in South Africa